Phase 2 trial (NEJM, 2023) The landmark Phase 2 trial, published in the New England Journal of Medicine, randomized 338 adults with obesity to receive weekly subcutaneous retatrutide at doses of 1 mg, 4 mg, 8 mg, or 12 mg, or placebo, for 48 weeks
Print pages only if youd like to (the trackers are especially handy in printed form)
When you join Calibrate, youll complete a Comprehensive Health Intake, including blood work, that your Calibrate clinician will carefully review before customizing your treatment plan and prescribing your medication
Nausea, vomiting, and other gastrointestinal symptoms are common, particularly when starting or increasing the dose and in T1D trials, these rates were similar to those seen in T2D and obesity trials
this theory warrants further study, he says
Throughout this process, it is crucial to avoid unapproved compounded products or research chemicals. The FDA has warned about dosing errors and adverse events from compounded semaglutide and other non-approved GLP-1 formulations sold online
